Alere ALR 深 沪
等待开盘 11-04 09:30:00 美东时间
1.32
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.32
- 总市值 4417.53万
- 52周最高 2.70
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.5487
- 委 比 0.00%
- 总股本 3346.61万
- 历史最高 559.90
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.5487
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多最新！强生拟分拆骨科业务，又一百亿美元分拆案
（来源：医趋势） 10月14日，据华尔街消息，强生公司周二宣布，计划将其骨科业务分拆为独立公司；同时，其公布的2025年第三季度财报超出华尔街预期，并上调了...
10-15 15:46
BioRestorative Therapies Reveals $1.085M Registered Direct Offering Priced Above Market
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced
10-07 02:31
马田雨：以用户为中心：AI驱动的充电设施全生命周期价值管理探索
专题：2025中国汽车充换电生态大会 9月27日-29日，2025中国汽车充换电生态大会在安徽省合肥市举办。本届大会以“十年奋进，智启未来...
09-30 09:28
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
Alterity Therapeutics announced positive results from its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA). The study showed that ATH434, at 50 mg and 75 mg doses, slowed disease progression and was well tolerated. Key findings included reduced disease severity, improvement in core symptoms, and maintained function in daily activities. The drug also reduced iron accumulation in affected brain regions, indicating target engagemen...
09-15 11:25
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
Alterity Therapeutics announced a successful capital raise of A$20 million to fund the development of its lead drug ATH434 for treating neurodegenerative diseases like MSA. CEO David Stamler highlighted positive Phase 2 trial results and the company’s strategic focus on advancing regulatory and clinical activities. Proceeds will strengthen Alterity’s balance sheet, support ongoing research, and facilitate potential partnerships.
09-08 11:35
Alterity Therapeutics to Present at the Biotech Showcase
Alterity Therapeutics, a biotech company focused on neurodegenerative disease treatments, announced that CEO David Stamler will present a corporate update at the Biotech Showcase on September 3, 2025, in Australia, and September 2, 2025, in the U.S. The presentation will highlight the company's lead asset, ATH434, and its drug discovery platform. Zoom webcast registration details and contact information for investors and media are provided. The a...
09-02 11:25
"Healthcare Entrepreneur Ron Zwanziger Threatens 'Adversarial Path' For Orasure Technologies After Company Rebuffs Takeover Bid, Letter Says" - Reuters Exclusive
Orasure stock price has dropped 11% in 4 weeks, 32% in 12 monthsZwanziger offered $3.50-$4 a share, price now under $3/shareOrasure Tech makes COVID-19 rapid-antigen testsLetter says $40 million share repurchase program
08-26 00:03
海信推出TriChroma激光电视L9Q
海信正式推出海信TriChroma激光电视L9Q。L9Q具有5000 ANSI流明的亮度和5000:1对比度，通过三重激光技术实现精准光线控制与鲜活色彩还原。...
08-15 17:11
特浦朗克全新升级品牌亮相2025国际铝展，创新技术引领铝加工绿色发展
上海，2025年7月9日，2025年中国国际铝工业展览会现场——今日(7月9日)，备受瞩目的2025年中国国际铝工业展览会在上海新国际博览中心盛大开幕。特浦...
07-09 16:04
ALR Technologies Completes Manufacturing Agreement for GluCurve Pet CGM
ALR Technologies ( ($ALRTF) ) just unveiled an update. ALR Technologies SG Ltd....
06-27 01:57
